Advertisement
News
Advertisement

AMAG Pharma gets takeover bid to stop Allos merger

Wed, 08/03/2011 - 6:45am
Mass High Tech: The Journal of New England Technology

MSMB Capital Management, a New York-based fund specializing in long-term strategic investments in health care and biotechnology, has made an unsolicited bid to acquire AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) for $378 million, to block the proposed merger between AMAG and Allos Therapeutics.

Cambridge-based AMAG issued a statement saying its board of directors would evaluate the offer and make a recommendation to shareholders. The proposed deal between AMAG and Allos is worth $686 million and would give Allos a 39 percent stake in the new joint company.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading